Liang Xiu

1.6k total citations · 1 hit paper
21 papers, 1.0k citations indexed

About

Liang Xiu is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Liang Xiu has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Hematology. Recurrent topics in Liang Xiu's work include Acute Myeloid Leukemia Research (6 papers), Virus-based gene therapy research (5 papers) and Multiple Myeloma Research and Treatments (5 papers). Liang Xiu is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Virus-based gene therapy research (5 papers) and Multiple Myeloma Research and Treatments (5 papers). Liang Xiu collaborates with scholars based in United States, China and United Kingdom. Liang Xiu's co-authors include Sen Hong Zhuang, James W. Curtsinger, Wayne Rackoff, Zhilong Yuan, Robert Z. Orlowski, Trilok Parekh, Heather J. Sutherland, Jesús F. San Miguel, Arnon Nagler and Ivan Špıčka and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Liang Xiu

21 papers receiving 972 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

2007 505 citations Robert Z. Orlowski, Arnon Nagler et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Liang Xiu

Since Specialization

Citations

This map shows the geographic impact of Liang Xiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang Xiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang Xiu more than expected).

Fields of papers citing papers by Liang Xiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liang Xiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang Xiu. The network helps show where Liang Xiu may publish in the future.

Co-authorship network of co-authors of Liang Xiu

This figure shows the co-authorship network connecting the top 25 collaborators of Liang Xiu. A scholar is included among the top collaborators of Liang Xiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang Xiu. Liang Xiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis 2024 ·Therapeutic Innovation & Regulatory Science ·James Signorovitch, Jialü Zhang, David T. Brown, Preston Dunnmon, Liang Xiu, Nicolae Done, (unknown), Yolanda Barbáchano, Isabelle Lousada	1
2	Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy 2023 ·Haematologica ·Thomas Pabst, Norbert Vey, Lionel Adès, Ulrike Bacher, Mario Bargetzi, Samson Fung, Gianluca Gaïdano, Domenica Gandini, Anna Hultberg, Amy J. Wagoner Johnson, Xuewen Ma, Rouven Müller, Kerri Nottage, Cristina Papayannidis, Christian Récher, Carsten Riether, (unknown), (unknown), Liang Xiu, Adrian F. Ochsenbein	25
3	Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models 2021 ·Human Gene Therapy ·(unknown), Liang Xiu, (unknown), (unknown), Jinfa Gu, Lanying Sun, (unknown), Jinqing Hu, (unknown), Xinyuan Liu	2
4	Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model 2021 ·Cancer Immunology Immunotherapy ·(unknown), Liang Xiu, (unknown), (unknown), Jinfa Gu, Lanying Sun, Jing Xiao, Jinqing Hu, (unknown), Xinyuan Liu	12
5	Iron deficiency exacerbates cisplatin- or rhabdomyolysis-induced acute kidney injury through promoting iron-catalyzed oxidative damage 2021 ·Free Radical Biology and Medicine ·(unknown), (unknown), Xiaoqing Zheng, Liang Xiu, Zhigang Wang, (unknown), Xudong Zhao, Shougang Zhuang, Qiuhui Pan, Fenyong Sun, Wenjun Shang, Jonathan Barasch, Andong Qiu	21
6	The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing 2020 ·Cell Death and Disease ·(unknown), Liang Xiu, (unknown), (unknown), (unknown), (unknown), Jinfa Gu, (unknown), Lanying Sun, Jing Xiao, Jinqing Hu, Hao Yuan, (unknown), Xiaoting Jin, (unknown), Xinyuan Liu	23
7	CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy. 2020 ·Journal of Clinical Oncology ·(unknown), Angela Howes, (unknown), (unknown), Liang Xiu, Colleen Kane, Kerri Nottage	9
8	Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia 2017 ·Blood ·(unknown), Jianming He, Liang Xiu, (unknown), (unknown), Xavier Thomas	2
9	Relationship between Complete Remission and Overall Survival in Acute Myeloid Leukemia: A Report from Daco-016 and Daco-017 2017 ·Blood ·Jianming He, (unknown), Liang Xiu, (unknown), (unknown), Xavier Thomas	2
10	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma 2016 ·Cancer ·Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Liang Xiu, Andrew Cakana, Trilok Parekh, Jesús F. San Miguel	32
11	Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML) 2015 ·Advances in Therapy ·(unknown), Ansgar Lange, Andreas Güntert, (unknown), Joris Diels, Liang Xiu, Peter De Porre, (unknown)	8
12	Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from apost hocanalysis of a randomized phase III study 2014 ·Leukemia & lymphoma ·Jianming He, Liang Xiu, Peter De Porre, (unknown), Xavier Thomas	28
13	Characterization of a novel orthoreovirus isolated from fruit bat, China 2014 ·BMC Microbiology ·Tingsong Hu, Wei Qiu, Biao He, Yan Zhang, (unknown), Liang Xiu, Wendong Zhang, Gang Chen, (unknown), (unknown), Ying Zheng, (unknown), Yonghe Hu, Weiguo Zhou, Changchun Tu, Quanshui Fan, Fuqiang Zhang	35
14	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma 2014 ·Blood ·Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Liang Xiu, Trilok Parekh, Jesús F. San Miguel	1
15	Canine distemper virus utilizes different receptors to infect chicken embryo fibroblasts and vero cells 2011 ·Virologica Sinica ·Jun Chen, Liang Xiu, (unknown)	4
16	Overall Survival: A Gold Standard in Search of a Surrogate 2009 ·The Cancer Journal ·Sen Hong Zhuang, Liang Xiu, Yusri Elsayed	40
17	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression breakdown → 2007 ·Journal of Clinical Oncology ·Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Jesús F. San Miguel, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Sen Hong Zhuang, Trilok Parekh, Liang Xiu, Zhilong Yuan, Wayne Rackoff, Jean‐Luc Harousseau	505
18	The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study. 2006 ·Blood ·Robert Z. Orlowski, Sen Hong Zhuang, Trilok Parekh, Liang Xiu, Jean‐Luc Harousseau, (unknown)	19
19	Effect of density on age-specific mortality in Drosophila: a density supplementation experiment 1996 ·Genetica ·Aziz A. Khazaeli, Liang Xiu, James W. Curtsinger	34
20	Slowing of age-specific mortality rates in Drosophila melanogaster 1993 ·Experimental Gerontology ·(unknown), Liang Xiu, James W. Curtsinger	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact